Search hospitals > Ontario > LONDON
London Health Sciences Centre - University Hospital
Claim this profileLONDON, Ontario N6A 5A5
Global Leader in Inflammatory Bowel Disease
Global Leader in Ulcerative Colitis
Conducts research for Ulcer
Conducts research for Crohn's Disease
Conducts research for Osteoarthritis
184 reported clinical trials
10 medical researchers
Summary
London Health Sciences Centre - University Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Crohn's Disease, Osteoarthritis and other specialties. London Health Sciences Centre - University Hospital is involved with conducting 184 clinical trials across 193 conditions. There are 10 research doctors associated with this hospital, such as Michael Chu, MD, James Howard, MD, Vipul Jairath, and Habib R Khan, MD.Top PIs
Michael Chu, MDLondon Health Sciences Centre3 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Stroke
17 reported clinical trials
26 drugs studied
James Howard, MDLondon Health Sciences Centre6 years of reported clinical research
Studies Osteoarthritis
Studies Hip Osteoarthritis
7 reported clinical trials
16 drugs studied
Vipul JairathLondon Health Sciences Centre1 year of reported clinical research
Studies Inflammatory Bowel Disease
Studies Ulcer
11 reported clinical trials
10 drugs studied
Habib R Khan, MDLondon Health Sciences Centre2 years of reported clinical research
Studies Cardiomyopathy
Studies Arrhythmogenic Cardiomyopathy
3 reported clinical trials
5 drugs studied
Clinical Trials running at London Health Sciences Centre - University Hospital
Coronavirus
Heart Failure
Ulcerative Colitis
Post-Traumatic Stress Disorder
Atrial Fibrillation
Cardiomyopathy
Aortic Valve Stenosis
Osteoarthritis
Crohn's Disease
Inflammatory Bowel Disease
Volatile Anesthetics
for COVID-19
Patients suffering lung failure, possibly from COVID-19 or hypoxic lung failure, will need life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible by using drugs given through a vein. Unfortunately, these drugs are in short supply worldwide due to the high number of COVID-19 patients needing these machines. Another way to provide sleep is by using gases that are breathed in. These are used every day in operating rooms to perform surgery. These gases, also called "inhaled agents" can also be used in intensive care units and may have several important benefits for patients and the hospital. Research shows they may reduce swelling in the lung and increase oxygen levels, which allows patients to recover faster and reduce the time spent on a breathing machine. In turn, this allows the breathing machine to be used again for the next sick patient. These drugs may also increase the number of patients who live through their illness. Inhaled agents are widely available and their use could dramatically lesson the pressure on limited drug supplies. This research is a study being carried out in a number of hospitals that will compare how well patients recover from these illnesses depending on which type of sedation drug they receive. The plan is to evaluate the number who survive, their time spent on a breathing machine and time in the hospital. This study may show immediate benefits and may provide a cost effective and practical solution to the current challenges caring for patients and the hospital space, equipment and drugs to the greatest benefit. Furthermore, the study will be investigating inflammatory profile and neuro-cognitive profiles in ventilated patients. Finally, this trial will be a team of experts in sedation drugs who care for patients with proven or suspected COVID-19 who need lifesaving treatments.
Recruiting4 awards Phase 36 criteria
EB05
for Hospitalized COVID-19 Patients
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response. This in turn stimulates a pro-inflammatory cascade ("cytokine storm") as well as emergency myelopoiesis. This proinflammatory cascade is activated when viral-mediated cell damage occurs in the lungs, resulting in the release of damage-signaling alarmin molecules such as S100A8/A9 (Calprotectin), HMGB1, Resistin, and oxidized phospholipids. These damage-associated molecular patterns (DAMPs) are recognized by the pattern recognition receptor Toll-Like Receptor 4 (TLR4) found on macrophages, dendritic cells and other innate immune cells and result in additional release of pro-inflammatory molecules. Several recent studies have shown that S100A8/A9 serum levels in hospitalized COVID-19 patients positively correlate with both neutrophil count and disease severity. Taken together the DAMP-TLR4 interaction forms a central axis in the innate immune system and is a key driver of the pathological inflammation observed in COVID-19. We hypothesis that targeting the initial step in the signalling pathways of these DAMPs in innate immunity offers the best hope for controlling the exaggerated host response to SARS-CoV-2 infection. EB05 has demonstrated safety in two clinical studies (\>120 patients) and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans. Given, this extensive body of evidence we believe EB05 could ameliorate ARDS due to COVID-19, significantly reducing ventilation rates and mortality.
Recruiting0 awards Phase 2 & 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at London Health Sciences Centre - University Hospital?
London Health Sciences Centre - University Hospital is a medical facility located in LONDON, Ontario. This center is recognized for care of Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Crohn's Disease, Osteoarthritis and other specialties. London Health Sciences Centre - University Hospital is involved with conducting 184 clinical trials across 193 conditions. There are 10 research doctors associated with this hospital, such as Michael Chu, MD, James Howard, MD, Vipul Jairath, and Habib R Khan, MD.